VERU INC. 10-Q Summary: Quarter Ended June 30, 2024
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for VERU INC. for the period ended June 30, 2024. Veru is a late clinical-stage biopharmaceutical company focused on developing novel medicines for metabolic diseases (obesity), oncology, and acute respiratory distress syndrome (ARDS). Its commercial product portfolio includes the FC2 Female Condom. The company recently restated prior period financials due to errors in accounting for research and development expenses.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Nine Months Ended June 30, 2024 |
|---|---|---|
| Net Revenues | $3.95 million | $10.23 million |
| Gross Profit | $1.34 million (34% margin) | $3.17 million (31% margin) |
| Net Loss | $(10.97) million | $(29.27) million |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.22) |
| Cash and Cash Equivalents | $29.15 million (as of June 30, 2024) | N/A |
| Working Capital | $27.86 million | N/A |
| Total Liabilities | $27.01 million | N/A |
Material Changes vs. Prior Period
- Revenue Mix Shift: Net revenues increased 18% quarter-over-quarter but decreased 18% year-over-year for the nine-month period. This is driven by a significant decline in U.S. prescription channel sales (down 66% YTD) due to the bankruptcy of major customer The Pill Club, partially offset by a 17% increase in global public health sector sales.
- Expense Reduction: Research and development (R&D) expenses dropped significantly to $9.5 million for the nine months ended June 30, 2024, compared to $47.3 million in the prior year. This reflects a strategic refocus on the enobosarm obesity program and the suspension of other trials (e.g., sabizabulin for COVID-19).
- Liquidity Improvement: Cash balances increased from $9.6 million at September 30, 2023, to $29.2 million at June 30, 2024, primarily due to a $35.2 million public offering of common stock in December 2023.
- Restatement Impact: Prior year figures (2023) have been restated to correct R&D expense understatements, resulting in higher reported losses for the comparable 2023 periods.
Guidance, Outlook, and Risks
- Clinical Pipeline: The company is actively enrolling patients in the Phase 2b QUALITY clinical trial for enobosarm (obesity treatment) in combination with semaglutide. Topline results are expected in Q4 2024. Development of sabizabulin for ARDS is paused pending external funding.
- Liquidity Outlook: Management believes current cash and FC2 revenue will fund operations for the next 12 months. However, significant additional funding is required to advance drug candidates.
- Capital Raising Constraints: Due to late filings of the Q4 2023 10-Q and a required 8-K, the company is ineligible to file new Form S-3 registration statements until at least March 1, 2025. This impairs the ability to conduct underwritten offerings or use the Jefferies Sales Agreement unless non-compliance is waived.
- Legal and Contingencies: The company faces multiple shareholder derivative lawsuits regarding prior disclosures on sabizabulin. Additionally, there is uncertainty regarding the collection of $10 million in promissory notes from Onconetix Inc. (formerly Blue Water Vaccines) related to the sale of ENTADFI assets; a forbearance agreement is in place.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to complex transactions and R&D expense estimates. Remediation is ongoing.
Investor Verification Checklist
- Cash Runway: Verify if the $29.2 million cash balance is sufficient to fund the Phase 2b QUALITY trial and operations through the next 12 months without further dilution.
- Form S-3 Eligibility: Monitor the status of the late filings and the potential impact on the ability to raise capital between the 10-K filing and March 2025.
- ENTADFI Receivables: Assess the collectability of the remaining $10 million owed by Onconetix Inc. and the value of the preferred stock received as partial payment.
- Restatement Remediation: Confirm the effectiveness of new internal controls to prevent future accounting errors and restatements.
- FC2 Revenue Stability: Evaluate the sustainability of global public health sector sales given pricing pressures from large agencies and the loss of U.S. telehealth volume.